Overview

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Status:
Recruiting

Trial end date:
2027-10-14

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety and tolerability of opevesostat in the treatment of male Chinese participants with metastatic castration-resistant prostate cancer (mCRPC) and to characterize the pharmacokinetic profile of opevesostat. There are no formal hypotheses to be tested in this study.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Collaborator:

Orion Corporation, Orion Pharma

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate
Fludrocortisone
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate